RxDoctor Payments Data

Lindsey Shaw, APRN

Nurse Practitioner · Rogers, ARNPI 1518323542

Payments from drug & device makers

$3,980in general payments, 2019–2025

Across 205 payments — averaging $19.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$533
  • GSK$405
  • Regeneron Healthcare Solutions, Inc.$359
  • AstraZeneca$342
  • Sanofi$292
  • Grifols USA, LLC$282
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$3,90098%
  • Education$802%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,980 in reported general payments places this provider in the 90th percentile of 697 nurse practitioner providers in Arkansas.

See all nurse practitioner providers in Arkansas

Medicare billing

Part B allowed, 2024
$11,245
Medicare patients
96
Services billed
134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$25,482
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$21,996
Breo ElliptaFluticasone/Vilanterol20$7,893
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$7,635
Incruse ElliptaUmeclidinium Bromide17$6,665
Fluticasone-SalmeterolFluticasone Propion/Salmeterol26$3,369
Albuterol Sulfate HfaAlbuterol Sulfate129$2,794
Wixela InhubFluticasone Propion/Salmeterol11$1,126
Ventolin HfaAlbuterol Sulfate19$1,047
Roflumilast12$611
Montelukast Sodium51$529
Fluticasone Propionate21$242
Azithromycin20$167
Doxycycline Hyclate32$167
Prednisone61$144

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$405$47,67577 claims
AstraZenecaBreztri Aerosphere$342$21,99632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 697 nurse practitioner providers in Arkansas.

Other nurse practitioner in Rogers

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →